Holen Sie sich die Stockscreener-App
15.82
5.04%
-0.84
Handel nachbörslich:
15.72
-0.10
-0.63%
Schlusskurs vom Vortag:
$16.66
Offen:
$16.5
24-Stunden-Volumen:
4.31M
Relative Volume:
2.94
Marktkapitalisierung:
$1.55B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-33.66
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
-12.01%
1M Leistung:
-10.57%
6M Leistung:
+32.72%
1J Leistung:
+21.13%
1-Tages-Spanne:
$14.50
$16.65
1-Wochen-Bereich:
$14.50
$18.00
52-Wochen-Spanne:
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
15.82 | 1.64B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharma Sales Jump 3,040% in Q2 - The Motley Fool
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization - AInvest
ARS Pharmaceuticals reports reports Q2 EPS (46c), consensus (51c) - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - sharewise.com
SPRY Plummets 11.5%: What's Behind the Sharp Decline? - AInvest
Transcript : ARS Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
ARS Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q2 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises - MarketScreener
ARS Pharmaceuticals earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
ARS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q2 Revenue $15.7M, vs. FactSet Est of $13.8M - MarketScreener
ARS Pharma (SPRY) 8-K: Q2 Results & Updated Investor Presentation Filed | SPRY SEC FilingForm 8-K - Stock Titan
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - Yahoo Finance
TR | OpenAI4o Maintains ARS Pharmaceuticals(SPRY.US) With Hold Rating, Cuts Target Price to $16.5 - 富途牛牛
What drives ARS Pharmaceuticals Inc.’s stock priceShort-Term Explosive Growth - 선데이타임즈
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
ARS Pharmaceuticals SPRY 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments - AInvest
What are the risks of holding ARS Pharmaceuticals Inc.Maximum Return Portfolio Ideas - thegnnews.com
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
How strong is ARS Pharmaceuticals Inc. company’s balance sheetTriple-digit profit margins - Jammu Links News
Does ARS Pharmaceuticals Inc. stock perform well during market downturnsStay ahead with advanced stock screening tools - Jammu Links News
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockGet expert alerts on market-moving stocks - Jammu Links News
ARS Pharmaceuticals Inc. Stages Intraday Comeback — Trend ChangeConservative Long Term Growth Plans Under Review - beatles.ru
What are ARS Pharmaceuticals Inc. company’s key revenue driversDaily Trading Strategy For Smart Trading - jammulinksnews.com
What is ARS Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Watchlist That Work - jammulinksnews.com
Why is ARS Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Picks With High Returns - Jammu Links News
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength - Yahoo Finance
Quant Models Detect Momentum Reversal in ARS Pharmaceuticals Inc.Trend Analysis for Safer Trades Gains Popularity - metal.it
ARS Pharmaceuticals Inc. Stock Approaches Key Moving AverageConservative Entry for High Return Setup Backed - beatles.ru
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ARS Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsTarget Return Focused Trade Insights Shared - metal.it
What institutions are buying ARS Pharmaceuticals Inc. stock nowReal Time Stock Movement Analysis Indicates Breakout - metal.it
When is ARS Pharmaceuticals Inc. stock expected to show significant growthProven strategies for superior portfolio growth - Jammu Links News
Published on: 2025-07-28 04:26:33 - jammulinksnews.com
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):